Data from LEVEL UP Trial with Upadacitnib in Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis.
EP: 1.Heterogenous Presentation of Atopic Dermatitis
EP: 2.Burden of Atopic Dermatitis and its Impact on Patient’s Quality of Life
EP: 3.Patient’s Goals and Atopic Dermatitis Treatment Selection
EP: 4.Talking to Patients about Atopic Dermatitis Treatment Response
EP: 5.Use of PRO in Atopic Dermatitis Clinical Practice
EP: 6.Incorporating Patient Preferences in the Treatment of Atopic Dermatitis
EP: 7.Changing Standard of Care in Atopic Dermatitis
EP: 8.Unmet Needs and Gaps in AD
EP: 9.Looking Beyond Type 2 Inflammation in Atopic Dermatitis
EP: 10.JAK Inhibitors in Atopic Dermatitis
EP: 11.Safety Profile of JAK Inhibitors and their Use in Atopic Dermatitis
EP: 12.Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis
Now Viewing
EP: 13.Data from LEVEL UP Trial with Upadacitnib in Atopic Dermatitis
Video content above is prompted by the following:
- Please discuss Level Up data with upadacitinib that were recently presented at RAD 2024.
- What are clinical implications of these data for everyday practice?
Recent Videos
Related Content
